Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOCHA: Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents
NCT03497676Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of cabotegravir, rilpivirine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2019; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03497676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03497676.